# Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia

> **NCT02896829** · — · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 97 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **BEHAVIORAL:** Interruption of the treatment by Imatinib

## Key facts

- **NCT ID:** NCT02896829
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-03
- **Primary completion:** 2019-04
- **Final completion:** 2019-04
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2020-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896829, "Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02896829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*